DUBLIN, June 23, 2021 /PRNewswire/ -- The "Malignant Ascites Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 ...
The MarketWatch News Department was not involved in the creation of this content. -- Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor ...
The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The ascites ...
BioVie’s stock has moved up considerably over the past 9 months in light of promising Alzheimer’s data. BioVie Day and full Phase 2 Parkinson’s trial results are scheduled for this month. BioVie has ...
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Martin Pharmaceuticals, a clinical-stage pharmaceutical company targeting complications of advanced liver disease, today announced that results from its DREAM ...
Ascites is a common complication of cirrhosis of the liver. Build-up of fluid causes the abdomen to swell and may lead to discomfort, difficulty breathing, fatigue, nausea and poor appetite. Treatment ...
Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer. This is an ASCO Meeting ...
BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results